Pfizer Licenses Xoma’s BCE Antibody Technology
This article was originally published in The Pink Sheet Daily
Xoma to receive $30 million up-front payment.
You may also be interested in...
Xoma 052 targets interleukin-1 beta to stop destruction of pancreatic cells.
Agreement now could earn California company $230 million before royalties for identifying therapeutic antibodies that target cancer.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee